INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- University of Texas Southwestern Medical Center
- Study ID
- NCT03953976
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intensity modulated radiation therapy (IMRT) — RADIATIONIntensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
Study Details
Elective nodal irradiation has been a longstanding standard-of-care in the management of mucosal squamous cell carcinoma of the head and neck. Recent studies have suggested that reduced elective dose and volume may be a viable approach to improve toxicity. In this study, we are eliminating the elective neck treatment, focusing therapy on involved and suspicious nodes.
Key Dates
- Start date
- Jul 23, 2019
- Status verified
- Oct 2025
- Primary completion
- Nov 15, 2022
- Completion
- Jan 22, 2024
Study Design
- Enrollment
- 67 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: PET-CT at 3 months and ENT evaluationTreatment to the gross primary and nodal disease (70 Gy), with suspicious nodes treated to 66.5 Gy, all in 35 fractions. CT and PET-CT are required for nodal assessment. Restaging PET-CT must be performed between 11-14 weeks from the completion of treatment. The patient must see an otolaryngologist after the PET-CT to decide on post-treatment neck dissection per the surgeon's judgement. Patients will then be seen every 3 months (+/- 2 weeks) for the first year, and then at least every 6 months (+/-2 weeks) until the 36 month. Subsequent and intervening follow-up visits will be made per physician preference
Primary Outcome Measure
Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Southwestern Medical Center - Dallas | Dallas | Texas | 75390 | - |
Find similar trials in Dallas, TX
By condition
Related Studies
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPHASE2 · Recruiting · ECOG-ACRIN Cancer Research Group · Birmingham, Alabama
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas